Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: Results in 1005 patients
Annals of Oncology, 11/10/09

Laé M et al. – This study showed that 5.1% of invasive bladder carcinomas had a HER2 gene amplification. These findings may have clinical implications for the management of patients with HER2-positive locally advanced or metastatic bladder cancer, as they could be potential candidates for targeted therapy.

Methods

1005 patients
Paraffin-embedded tissues of transurethral resection or cystectomy evaluated by immunohistochemistry (IHC), using antibodies against HER2
All samples with a 2+ or 3+ HER2 overexpression evaluated by FISH

Results

HER2 overexpression observed in 93 (9.2%) tumors (2+: 42 tumors and 3+: 51 tumors)
Using FISH, all HER2 3+ tumors had gene amplification
No amplification found in 2+ tumors
Intratumoral heterogeneity observed in 35% of cases
Tumors showed same heterogeneous pattern, with adjacent 3+ positive and negative areas by both IHC and FISH

<< Previous
Pregnancy after breast cancer: The importance of active...

Next >>
The location of lymphangiogenesis is an independent prognostic...